The U.S. regulator shared the roadmap for implementing the program, first proposed in August 2025, and teased changes made in response to industry feedback.
The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...
Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is “the ...
In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback